Aleah Caulin

Aleah Caulin is the Vice President of Nonclinical at Peel Therapeutics, a clinical-stage biotech company focused on developing medicines inspired by evolutionary biology. In her role, she strategically designs, oversees, and analyzes nonclinical studies related to the company’s drug development programs.45

Professional Background

Before her current position, Caulin served as the Director of Preclinical Studies at Peel Therapeutics from January 2019 to July 2021. She has also held various roles in product development and bioinformatics at Driver, a health-tech startup aimed at connecting cancer patients with clinical trials.14

Education

Caulin earned her Ph.D. in Genomics and Computational Biology from the University of Pennsylvania, where her research focused on the evolution of cancer suppression in large, long-lived organisms, such as elephants and whales. She also holds a Bachelor of Science degree in Biology and Computer Science from Boston College.15

Contributions to Research

Recently, Caulin presented significant findings at the Society for Immunotherapy of Cancer Annual Meeting, discussing the promising results of a combination therapy involving PEEL-224, a lead clinical asset of Peel Therapeutics, in a mouse model of colon cancer.23 Her work emphasizes the potential of PEEL-224 to improve treatment outcomes for solid tumors, showcasing her commitment to advancing cancer therapies.

Personal Interests

Outside her professional life, Caulin has diverse interests, including a unique past experience as a dock master at a marina and having owned a five-foot green iguana as a pet.5